恶性脑胶质瘤中EphA2、EphrinA1表达与预后的关系

Altered expression of EphA2 and EphrinA1 is associated with prognosis of malignant glioma patients

目的 检测受体酪氨酸激酶EphA2和其配体EphrinA1在恶性脑胶质瘤中的表达,并探讨其与患者预后的关系.方法 选取68例原发性恶性脑胶质瘤（Ⅲ或Ⅳ级）入组,患者在手术全切除肿瘤的基础上接受规范的放化疗,并行长期随访.免疫组化SABC法检测肿瘤标本中EphA2、EphrinA1的表达水平,并结合患者的随访资料进行统计学分析.结果 68例标本中,52例EphA2表达阳性,28例EphrinA1表达阳性;EphA2和EphrinA1的表达水平与肿瘤病理分级相关,Ⅲ级肿瘤的EphA2表达水平低于Ⅳ级肿瘤,而Ⅲ级肿瘤的EphrinA1表达水平高于Ⅳ级肿瘤.肿瘤标本呈EphA2阴性、弱阳性表达的患者预后显著优于EphA2中度阳性、强阳性表达的患者,EphrinA1表达水平不同的患者预后差异无统计学意义,EphA2阳性/EphrinA1阴性表达的患者预后显著差于EphA2阳性/EphrinA1阳性,EphA2阴性/EphrinA1阳性和EphA2阴性/EphrinA1阴性表达的患者.结论 EphA2是恶性脑胶质瘤的预后相关因子,同时检测EphA2和EphrinA1的表达对于评估恶性胶质瘤患者的预后具有重要意义.

Objective Malignant gliomas display over- expression of the receptor tyrosine kinase EphA2.However,expression levels of the EphA2 ligand,EphrinA1,have not been fully elucidated.This study aims to determine the expression of EphA2/EphrinA1 in detail,and further detect the predictive roles of EphA2 /EphrinA1 for prognosis of malignant glioma patients.Method Sixty- eight patients with primary gliomas （grade Ⅲ or Ⅳ） were included in this study.The expression of EphA2 and EphrinA1 in tumors was assessed by immunohistochemistry and was statistically analyzed in combination with the follow- up data of patients.Methods of 68 cases,52 cases were EphA2- positive and 28 were EphrinA1- positive.The increased EphA2 expression was associated with higher grade histology and poor patient prognosis.On contrary to this,the increased EphrinA1 expression was associated with lower grade histology,but not associated with poor patient prognosis.Moreover,patients with tumors positive for EphA2 and negative for EphrinA1 had significantly shorter overall survival than patients with tumors positive for both EphA2 and EphrinA1,negative for both EphA2 and EphrinA1,or negative for EphA2 and positive for EphrinA1.Conclusion These data indicate that altered expression of EphA2 and EphrinA1 may correlate with prognosis of malignant glioma patients.